AHA Comments on DEA’s Proposed Aggregate Production Quotas for Controlled Substances, Schedule I and II

The AHA appreciates the opportunity to comment on the Drug Enforcement Administration’s proposed notice on aggregate production quotas for schedule I and II controlled substances.

We believe that in its intense focus on diversion, the DEA must also address another critical challenge – ensuring enough medication to fulfill legitimate and critical medical needs.

To ensure that legitimate medical needs are met, it is essential that drug shortages be explicitly considered in setting and adjusting aggregate production quotas and that resolving shortages be deemed as a relevant factor considered in the procedures for applying for and fixing individual manufacturing quotas. Proactively considering shortages will safeguard patient health and safety and ensure critical needs are met.

Furthermore, we continue to recommend that the DEA routinely consult with the FDA’s drug shortage staff, which collects and publishes relevant data on all national drug shortages, when establishing and adjusting quotas.

Related Resources

Case Studies
Public
To meet the demand for health care workforce development and expansion, New York’s Staten Island Performing Provider System (SI PPS) partnered with the College…
Letter/Comment
Public
The AHA, American Society of Anesthesiologists, American
Letter/Comment
Public
The AHA recognizes that SAMHSA is statutorily constrained in making structural amendments to the regulations under 42 CFR Part 2;
Press Releases
Public
Tom Nickels Executive Vice President American Hospital Association
Letter/Comment
Public
The AHA and six other organizations comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas.
AHA Center for Health Innovation Market Scan
In what is being hailed as a model for provider-led innovation, Civica Rx, the startup formed last year by a group of health systems to combat rising drug…